Last reviewed · How we verify
ibuprofen Formulation 1
At a glance
| Generic name | ibuprofen Formulation 1 |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis (PHASE2)
- Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III) (PHASE1, PHASE2)
- Evaluation of Hydrogen Peroxide and Hyaluronic Acid (BMG0703) in the Healing of Post-extraction Sites (PHASE3)
- Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial (PHASE2)
- A Study to Assess Disintegration of the New Aspirin Disintegrating Tablets (PHASE1)
- Ibuprofen Bioavailability Trial With Oral Single Dose Administration. (PHASE1)
- Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS) (PHASE3)
- Bioequivalence Study of Ibuprofen 400 mg/10 mL Oral Suspension vs. MOMENTACT 400 mg Film-coated Tablet (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ibuprofen Formulation 1 CI brief — competitive landscape report
- ibuprofen Formulation 1 updates RSS · CI watch RSS
- Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI